Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action

摘要

This invention provides methods of decreasing apolipoprotein B-containing lipoprotein and of treating atherosclerotic diseases and dyslipidemic diseases by reducing plasma phospholipid transfer protein activity, and methods of identifying chemical compounds for use in such treatments.